These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26088338)

  • 1. Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH.
    Abdullah I; Chee CF; Lee YK; Thunuguntla SSR; Satish Reddy K; Nellore K; Antony T; Verma J; Mun KW; Othman S; Subramanya H; Rahman NA
    Bioorg Med Chem; 2015 Aug; 23(15):4669-4680. PubMed ID: 26088338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
    Zeng H; Zhang H; Jang F; Zhao L; Zhang J
    Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors.
    Wu K; Chen M; Peng X; Li Y; Tang G; Peng J; Cao X
    Mini Rev Med Chem; 2022; 22(19):2438-2462. PubMed ID: 35319364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
    Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
    Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
    White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
    J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Luo Y; Liu X; Shi Y; Klinghofer V; Johnson EF; Frost D; Donawho C; Jarvis K; Bouska J; Marsh KC; Rosenberg SH; Giranda VL; Penning TD
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3955-8. PubMed ID: 18586490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
    Lucas-Hourani M; Munier-Lehmann H; El Mazouni F; Malmquist NA; Harpon J; Coutant EP; Guillou S; Helynck O; Noel A; Scherf A; Phillips MA; Tangy F; Vidalain PO; Janin YL
    J Med Chem; 2015 Jul; 58(14):5579-98. PubMed ID: 26079043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH).
    Munier-Lehmann H; Lucas-Hourani M; Guillou S; Helynck O; Zanghi G; Noel A; Tangy F; Vidalain PO; Janin YL
    J Med Chem; 2015 Jan; 58(2):860-77. PubMed ID: 25558988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
    Morales J; Li L; Fattah FJ; Dong Y; Bey EA; Patel M; Gao J; Boothman DA
    Crit Rev Eukaryot Gene Expr; 2014; 24(1):15-28. PubMed ID: 24579667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
    Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
    Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of PARP and protein poly-ADP-ribosylation process in regulation of cell functions].
    Drel' VR; Shymans'kyĭ IO; Sybirna NO; Velykyĭ MM
    Ukr Biokhim Zh (1999); 2011; 83(6):5-34. PubMed ID: 22364016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid phase combinatorial synthesis of 1,2,5-trisubstituted benzimidazole derivatives as human DHODH inhibitors.
    Sitwala ND; Vyas VK; Variya BC; Patel SS; Mehta CC; Rana DN; Ghate MD
    Bioorg Chem; 2017 Dec; 75():118-126. PubMed ID: 28941392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
    Oh KS; Lee S; Yi KY; Seo HW; Koo HN; Lee BH
    J Pharmacol Exp Ther; 2009 Jan; 328(1):10-8. PubMed ID: 18836068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.